Table 1.
Cell Type | Material | Biophysical Property | Biological Model | Origin/Cell line | Biological effect | Reference |
---|---|---|---|---|---|---|
Neutrophils | Titanium | Hydrophilicity | In vitro | C57BL/6J mice | ↓ Cytokine release ↓ NET formation |
76 |
Hydrophilicity | In vitro | Human PBMC | ↓ Cell activation ↓ ROS generation |
230 | ||
Titanium PEEK | Roughness Hydrophilicity | In vivo | New Zealand White Rabbits | ↑ Neutrophils on PEEK | 231 | |
PDO | Architecture | In vitro in vivo | Human PBMC (in vitro) Sprague-Dawley rats (in vivo) | ↓ NET formation on large diameter fibers ↓ Net formation in vivo |
232 | |
PDMS | Stiffness | In vitro | C57BL/6J mice | ↑ NET formation | 233 | |
Polyacrylamide | Stiffness | In vitro | Human PBMC | ↓ Migration speed ↑ Spreading ↑ NET formation with LPS treatment |
84 | |
Polyacrylamide | Stiffness | In vitro | Murine myeloid progenitor | ↑ Spreading | 234 | |
PEG-Gelatin | Hydrophilicity | In vitro | Human PBMC | ↑ MPO release ↓ MMP-9 | 235 | |
PTFE Dacron | Hydrophobicity | In vitro in vivo | Human PBMC | ↑ Cell death ↑ ROS generation |
83 | |
PTFE | Hydrophobicity | In vitro | Human PBMC | ↑ Net formation ↑ Histone citrullination ↑ Elastase and ROS generation |
236 | |
Macrophages | Titanium | Roughness | In vitro | THP-1 | ↑ Pro- and anti-inflammatory markers | 125 |
Roughness | In vitro | RAW 264.7 | ↑ Cell elongation ↑ Chemokine levels |
127 | ||
Macrophages | Titanium | Roughness | In vitro | RAW 264.7 | ↑ Pro-inflammatory markers | 130 |
Roughness Hydrophilicity | In vitro | C57BL/6J mice | ↓ Pro-inflammatory cytokines ↑ M2 phenotype |
80 | ||
Roughness | In vitro | J774A.1 | ↓ Nitric oxide, iNOS, and pro-inflammatory cytokines | 141 | ||
Roughness | In vitro | J774.A1 | ↓ Pro-inflammatory cytokines | 142 | ||
Roughness | In vitro in vivo | C57BL/6J mice | 30 nm structures ↑ M2 phenotype 100 nm structures ↑ M1 phenotype | 147 | ||
Roughness Hydrophilicity | In vitro in vivo | C57BL/6J mice | ↑ M2 phenotype ↑ Anti-inflammatory cytokines ↓ Pro-inflammatory cytokines |
77 | ||
Roughness Hydrophilicity | In vitro | C57BL/6J mice | ↓ IL-1β, IL-6, TNF ↑ IL-4, IL-10 |
78 | ||
Roughness Hydrophilicity | In vitro | RAW 264.7 | ↓ Pro-inflammatory cytokine ↑ Anti-inflammatory cytokines |
149 | ||
Roughness Hydrophilicity | In vitro | THP-1 | ↓ Pro-inflammatory cytokines | 148 | ||
Hydrophilicity | In vitro | RAW 264.7 | ↓ Pro-inflammatory cytokines | 150 | ||
Roughness Hydrophilicity | In vitro | Human PBMC | ↓ Pro-inflammatory cytokines ↑ M2 phenotype |
152 | ||
Hydrophilicity Hydrophobicity | In vitro | Human PBMC | ↑ Anti-inflammatory cytokines on hydrophilic material | 156 | ||
Titanium Titanium alloy | Roughness Hydrophilicity | In vitro | C57BL/6J mice | ↓ IL-1β, IL-6, TNF ↑ IL-4, IL-10 |
132 | |
Titanium Titanium alloy | Roughness Hydrophilicity | In vitro | C57BL/6J mice | ↑ Anti-inflammatory cytokines ↓ Pro-inflammatory cytokines |
133 | |
Macrophages | Titanium PEEK | Roughness Hydrophilicity | In vivo | New Zealand White Rabbits | ↑ Macrophages on PEEK ↑ M2 phenotype on Titanium |
231 |
Titanium alloy | Architecture | In vitro | RAW 264.7 | ↓ Metabolism ↓ Pro-inflammatory cytokines |
140 | |
PLLA | Architecture | In vitro | RAW 264.7 | ↑ Anti-inflammatory phenotype | 144 | |
PLGA | Hydrophilicity | In vitro | RAW 264.7 | ↓ Cell activation ↓ Pro-inflammatory cytokines |
153 | |
PCL | Roughness | In vitro In vivo | C57BL/6J (in vitro) Sprague-Dawley rats (in vivo) | ↑ Cell elongation ↑ Arginase 1 and IL-10 expression ↑ Anti-inflammatory phenotype |
128 | |
Architecture | THP-1 (in vitro) Sprague Dawley rats (in vivo) | ↑ M1 phenotype on random alignment | 237 | |||
PLLA-PCL | Architecture | In vitro in vitro | Sprague-Dawley rats | ↑ IL-10 and Arg1 ↓ TNF and iNOS ↑Anti-inflammatory phenotype |
145 | |
PEEK | Hydrophilicity | In vitro | RAW 264.7 | ↓ Pro-inflammatory cytokines ↑ Anti-inflammatory cytokines |
154 | |
Polyethylene | Architecture | In vitro | C57BL/6J mice | ↑ Anti-inflammatory cytokines ↓ TNF |
126 | |
Polyvinylidene fluoride | Roughness | In vitro | Human PBMC | ↑ Pro- and anti-inflammatory activation | 131 | |
Polystyrene | Hydrophilicity | In vitro | Human PBMC | ↑ Anti-inflammatory cytokines | 238 | |
Tricalcium phosphate | Roughness | In vitro | RAW 264.7 | ↑ iNOS and IL-1β | 114 | |
Hydroxyapatite | Roughness | In vitro | RAW 264.7 | ↑ M2 phenotype ↓ M1 phenotype |
143 | |
DC | Titanium | Roughness Hydrophilicity | In vitro | Human PBMC | ↑ CD86 ↓ IL-10, IL-1ra, MCP-1, IL-8 |
178 |
DC | Polystyrene PTFE PMMA | Hydrophilicity Hydrophobicity Architecture | In vitro | Human PBMC | ↑ Activation and migration on smooth surfaces | 183 |
MC | Titanium | Roughness | In vitro | RBL-2H3 | ↑ Adhesion ↑ Proliferation ↑ Migration |
194 |
PLGA | Hydrophilicity | In vivo | Balb/c mice | ↑ Cell recruitment ↑ Degranulation |
239 | |
PDO | Architecture | In vitro | C57BL/6J mice | ↓ IL-6 and TNF ↑ VEGF |
240 | |
PDO PCL Fibroin |
Chemistry Architecture | In vitro | C57BL/6J mice | ↑ Adhesion on polymers ↑ Proliferation on polymers ↑ TNF, MCP-1, and IL-13 on polymers |
241 | |
Polypropylene | Hydrophilicity | In vivo | Wistar rats | ↑ Cell number ↑ NADPH |
242 | |
Polystyrene | Architecture | In vitro | NCL-2 | ↑ Proliferation | 243 | |
NK | PDMS | Stiffness | In vitro | Human PBMC | Bell shaped of NK adhesion and CD107 expression in response to stiffness ↑ Activation in response to stiffness |
221 |
Architecture | In vitro | NK-92MI | ↑ NK cytotoxicity on large microwells | 229 | ||
PLA Chitosan | Architecture | In vitro | Human PBMC | ↓ NK metabolism ↑ NK number |
244 |